This topic contains 0 replies, has 1 voice, and was last updated by  John Connor 1 month, 1 week ago.

  • Author
    Posts
  • #18404
     John Connor 
    Keymaster

    Our new report from#ECTRIMS2019 on another B cell therapy.

    B-cell therapies, which include approved MS therapy Ocrevus (ocrelizumab, by Roche) and rituximab (used off-label) continue to be seen as promising strategies for the treatment of MS.

    For Stephen L. Hauser, MD, an investigator in the ASCLEPIOS trials, these results represent a decades-long journey to better understand MS and what he calls a “magnificent success story” in the overall treatment of the disease.

    “Ofatumumab shuts down new focal inflammatory activity nearly completely. It reduces relapse-independent disability progression, and at least in the clinical trial data to date, it has a very favorable safety profile. I believe that clinicians should consider the use of highly effective therapy with an agent like ofatumumab very early in the disease course,”

    Good news? Sounds like it to me. What do you think?

    • This topic was modified 1 month, 1 week ago by  John Connor.
    • This topic was modified 1 month, 1 week ago by  Marta Ribeiro.
    • This topic was modified 1 month, 1 week ago by  Marta Ribeiro.

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account